Daclizumab May Reduce MS Disease Activity More Than Interferon Beta Alone

Daclizumab has reduced multiple sclerosis disease activity in previous non-randomised studies. In the current study, John W. Rose, MD, Neurovirology Research Laboratory, VA Medical Center, Salt Lake City, Utah and colleagues aimed to assess whether daclizumab reduces disease activity in patients with active relapsing multiple sclerosis who are receiving standard interferon beta treatment.